Physician profile
Ryan Shaffer
NPI 1679053813
$544.32
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.04 · 2023: $267 · 2024: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $73.41 | 2023-2024 | Otezla, Repatha |
| Novo Nordisk INC | $72.95 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $63.62 | 2023-2024 | |
| Abbvie INC. | $58.54 | 2023-2024 | |
| Axsome Therapeutics, INC. | $42.93 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $35.85 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.72 | 2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $22.80 | 2024 | Voquezna |
| Exact Sciences Corporation | $21.75 | 2023 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $21.75 | 2024 | Yupelri |
| Glaxosmithkline, LLC. | $20.12 | 2023 | Shingrix, Arexvy |
| Apria Healthcare LLC | $20.04 | 2021 | |
| Lilly USA, LLC | $19.96 | 2024 | Zepbound |
| Merck Sharp & Dohme LLC | $18.31 | 2023 | Verquvo, Belsomra, Steglatro |
| Paratek Pharmaceuticals, INC. | $15.15 | 2023 | Nuzyra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $13.42 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.